|CELESTIAL LABS LIMITED was incorporated as a Private Limited Company on November 19, 1997
as 'Celestial Technologies Private Limited'. The subscribers to the memorandum were Mr. Rajani Kanth
Katragadda and Mr. Vijay Marur. The company was later converted into a Public Limited Company under
the name 'Celestial Technologies Limited' on December 6, 1999 and has been subsequently renamed
as 'CELESTIAL LABS LIMITED' effective from February 13, 2004. The present promoter of the company
is Mr. Aditya Narayan Singh. The Original promoters sold their holding to the present promoter on 7.11.1998.
CELESTIAL LABS LIMITED is a Hyderabad based ISO 9001-2000 certified company. It has been providing
customized enterprise solutions, bioinformatics services and also involved in development of
biopharmaceuticals and industrial enzymes. CELESTIAL LABS is in contact with Centre for Cellular &
Molecular Biology (CCMB) under the aegis of Council for Scientific and Industrial Research, Ministry of
Science and Technology, Government of India and Indian Institute of Chemical Technology (IICT), premier
chemical and Biological Institutions in Hyderabad to work on collaborative research projects to be funded by
Department of Science and Technology New Delhi. The in-house research and development centre of
CELESTIAL LABS is recognized by the Department for Scientific and Industrial Research, Ministry of Science
and Technology, New Delhi.
Major Events in the history of the Company are given below:
1997 Incorporation of Company
1999 Conversion of Private Limited Company to Public Limited Company and Change of Management .
2004 ISO Certification
2004 Development of a denovo drug design tool' CELSUITE'
2004 Change of name from Celestial Technologies Limited to Celestial Labs Limited
2004 Developed a bio-molecule to treat Vitiligo
2005 Designed a bio-molecule to treat multi cancer
The company has developed a de novo drug design tool 'CELSUITE' to aid the pharma industry in
discovering new molecules for curing different diseases. This tool will enable the company not only to
design new molecules for its own purpose but also to provide the bio-informatics services to the various
pharma and biotech companies. This tool has filed for protection of the IPR under the Copy Right Act vide
Dairy no 147-151 /05 on 20.06.2005 to the department.
Based on the company's in silico expertise (applying bioinformatics tools), the company has developed
therapeutic molecules to treat Leucoderma and multiple cancers. The cloned molecules are being subjected
for purification by the wet lab procedures at the company's collaborative Institute, Department of Microbiology,
Osmania University, Hyderabad.
In the industrial biotechnology area, the company has signed the technology transfer agreement with IMTECH
Chandigarh (a very reputed Council of Scientific & Industrial Research organization) for the manufacture of two
industrial enzymes - alpha Amylase and alkaline Protease. Initially these would be marketed in India and later
The company has initiated setting up of a biotechnology facility to develop its drug molecules and manufacture
industrial enzymes. This facility would also include the research laboratories for carrying out further R & D
activities to develop new related products for reducing wrinkles / stretch marks and acceleration of wound
healing from the same chemical structure of vitiligo. The proposed facility will be set up at Shapoorji Pallonji
Biotech Park in Genome Valley at Hyderabad in Andhra Pradesh.
The company has also plans to cater to the laboratory process outsourcing by using innovative platform
technologies/services in the field of analytical laboratory and bio-computational systems. The company is
positioned to drive innovations and support activities in post genome advancements via clinical trials (CT)
and laboratory process outsourcing (LPO) to be a significant player in personalized medicine in select disease
- Celestial Labs Ltd has informed that the Board of Directors of the Company by a resolution passed by circulation has appointed Mr. Subhash C Srivastava as an Additional Director of the Company w.e.f. April 15, 2009.